Talon Private Wealth LLC Invests $639,000 in Exelixis, Inc. $EXEL

Talon Private Wealth LLC purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,896 shares of the biotechnology company’s stock, valued at approximately $639,000.

Several other institutional investors also recently bought and sold shares of EXEL. AQR Capital Management LLC increased its stake in Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after buying an additional 4,477,029 shares in the last quarter. Norges Bank acquired a new position in shares of Exelixis during the fourth quarter valued at approximately $106,460,000. UBS Group AG lifted its position in shares of Exelixis by 100.1% in the third quarter. UBS Group AG now owns 2,655,069 shares of the biotechnology company’s stock valued at $109,654,000 after acquiring an additional 1,328,087 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Exelixis by 1,821.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,188,105 shares of the biotechnology company’s stock valued at $52,075,000 after acquiring an additional 1,126,256 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Exelixis by 111.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,115,456 shares of the biotechnology company’s stock valued at $92,720,000 after acquiring an additional 1,113,916 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on EXEL. Barclays boosted their price target on Exelixis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 14th. Citizens Jmp raised their price objective on Exelixis from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Wednesday, June 24th. Stifel Nicolaus lifted their target price on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings cut shares of Exelixis from a “buy (b+)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $49.29.

Exelixis Stock Performance

Shares of Exelixis stock opened at $55.27 on Thursday. Exelixis, Inc. has a one year low of $33.76 and a one year high of $57.57. The company has a market cap of $13.89 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.63 and a beta of 0.42. The business’s 50 day moving average price is $53.54 and its 200 day moving average price is $47.46.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. The company had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 earnings per share. On average, analysts predict that Exelixis, Inc. will post 3.15 EPS for the current fiscal year.

Insider Activity

In related news, CFO Christopher J. Senner sold 34,901 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the sale, the chief financial officer owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. This represents a 3.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Dana Aftab sold 43,451 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the sale, the executive vice president owned 594,741 shares of the company’s stock, valued at approximately $29,945,209.35. The trade was a 6.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 219,170 shares of company stock worth $10,620,641. Insiders own 2.60% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.